Does Praluent Raise Blood Sugar?

Short answer

Current clinical data suggest Praluent does not raise blood sugar in a clinically meaningful way. It works by blocking PCSK9, a protein that primarily affects LDL cholesterol clearance, not glucose metabolism. Most studies show neutral or modestly favorable effects on fasting glucose and HbA1c.

How Praluent works in the body

Praluent (alirocumab) binds to PCSK9 and prevents it from destroying LDL receptors on liver cells. More LDL receptors mean more LDL is removed from the blood. Because PCSK9 is not a core regulator of insulin secretion or insulin sensitivity, the drug's primary action does not directly interfere with blood sugar control.

What the clinical trials show

Major PCSK9 inhibitor trials, including those involving alirocumab, have consistently shown neutral or slightly beneficial glycemic profiles:

• Fasting glucose levels generally remain stable or show minimal change.
• HbA1c (a measure of average blood sugar over 2 to 3 months) typically shows no significant increase.
• New-onset diabetes rates in trial participants did not meaningfully exceed those seen with placebo.

These findings align with the drug's mechanism, which does not involve pathways that promote insulin resistance or impair pancreatic beta-cell function.

Why some patients might still notice changes

Individual responses vary. Factors that can independently affect blood sugar include weight changes, diet modifications, reduced cardiovascular event burden, or changes in other medications after starting a potent lipid-lowering drug. If a patient notices glucose fluctuations after starting Praluent, it is more likely tied to these broader lifestyle or treatment changes than to the drug itself.

Praluent and patients with diabetes or prediabetes

Praluent is approved for adults with hypercholesterolemia or mixed dyslipidemia, including patients who already have diabetes or are at risk for it. Guidelines from the American Diabetes Association and the European Society of Cardiology recognize PCSK9 inhibitors as safe options for high-risk patients who need additional LDL lowering beyond statins. The absence of a signal for worsening glycemic control supports its use in these populations.

When to talk to your doctor

If you are monitoring blood sugar closely after starting Praluent, continue doing so as part of your routine care. Report any persistent changes in fasting glucose, increased thirst, or unusual fatigue to your healthcare provider. These symptoms should be evaluated in the context of your full medication regimen and overall metabolic health, rather than attributed to Praluent alone.